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GENETIC COUNSELOR UTILIZATION AND INTERPRETATION OF SOMATIC 
TUMOR TESTING IN EVALUATION FOR LYNCH SYNDROME  
Danielle Rae Williams, B.A.  
Advisory Professor: Maureen Mork, M.S.  
Lynch syndrome (LS) is a hereditary cancer predisposition syndrome characterized by increased risk 
for colorectal and uterine cancers. Individuals with pathogenic variants in the mismatch repair 
(MMR) genes (MLH1, MSH2/EPCAM, MSH6, PMS2) are diagnosed with LS and subsequently 
recommended to proceed with high risk screening protocols to increase prevention and early detection 
of LS-related cancers. Various tumor studies can help identify those at high risk for LS, but 
sometimes create uncertainty with discordant screening and germline results, leading to unexplained 
mismatch repair deficiency (UMMRD). Somatic testing of the MMR genes has created opportunities 
for resolving UMMRD, thus clarifying LS status and ensuring appropriate cancer surveillance. 
However, guidelines for such testing are currently limited. The purpose of this study was to examine 
current and hypothetical ordering practices of cancer genetic counselors for LS evaluation and to 
investigate participants’ interpretation of somatic MMR testing results. Two-hundred eligible 
participants were recruited through the National Society of Genetic Counselors listserv and answered 
questions regarding demographics, ordering practices, barriers to somatic MMR testing, theoretical 
patient scenarios, and need for further guidelines. Statistical analysis was done using Chi-square, 
Fisher exact, and Wilcoxon rank-sum tests while themes were identified from free-text responses. 
Most respondents did not include somatic MMR testing in the work-up for LS and did not routinely 
order this testing, but indicated interest in ordering this in conjunction with germline testing. The gap 
between preferred testing strategies and current ordering practices for somatic MMR testing may be 
due to reported laboratory and insurance-related barriers, particularly cost and coordination of tissue 
specimens. Nearly all individuals endorsed the need for additional guidelines for somatic MMR 
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testing, which could provide support to reduce barriers, encourage insurance coverage, and allow for 
appropriate screening recommendations for patients and family members of those with UMMRD.
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INTRODUCTION 
Lynch syndrome (LS), formerly known as hereditary nonpolyposis colorectal cancer (HNPCC), 
is one of the most prevalent and well-defined hereditary cancer syndromes (Lynch et al., 2015). It is 
caused by germline heterozygous pathogenic variants in the mismatch repair (MMR) genes (MSH2, 
MSH6, MLH1, and PMS2), as well as EPCAM. (Lynch et al., 2015; Tiwari et al., 2016; Pena-Diaz et al., 
2015). Individuals with LS have an increased lifetime risk for colorectal and uterine cancers as well as 
extracolonic cancers of the ovary, renal pelvis, stomach, small bowel, brain, and sebaceous gland 
compared to the general population (Lynch et al., 2015; Tiwari et al., 2016; Vasen et al., 1999). 
Individuals with LS tend to have an earlier age of diagnosis and a higher rate of multiple primary cancers 
than the general population (Lynch et al., 2015; Tiwari et al., 2016; Vasen et al., 1999).  
Microsatellite instability (MSI) analysis and immunohistochemistry (IHC) staining are often 
initial tumor screens used to identify individuals at increased risk for LS (Battaglin et al., 2018; Cohen et 
al., 2014; Tiwari et al., 2016). MSI analysis determines the mutation status of microsatellite repeats and 
those with more mutated sequences are deemed MSI-high, which can be an indication of MMR 
deficiency (Lynch et al., 2015; Pena-Diaz et al., 2015; Tiwari et al., 2016). IHC staining can be used to 
determine MMR protein status in the tumor; absence of staining in one or more of these proteins raises 
suspicion for a germline pathogenic variant in one of the MMR genes (Lynch et al., 2015; Pritchard, et 
al., 2012). MLH1 promoter hypermethylation and/or BRAF somatic mutation analyses also contribute to 
risk assessment as the presence of either MLH1 promoter hypermethylation or theV600E mutation in 
BRAF are associated with sporadic MSI-high tumors as opposed to LS (Deng et al., 2004; McGivern et 
al., 2004).  
In addition to MLH1 promoter hypermethylation and BRAF V600E mutations, biallelic (or 
“double”) somatic MMR mutations can also be responsible for some MMR deficient cancers in the 
absence of a germline mutation, also known as unexplained mismatch repair deficiency (UMMRD) 
(Mesenkamp et al., 2014; Sourrouille et al., 2012). UMMRD can be due to undetectable germline 
pathogenic variants and large rearrangements, somatic mosaicism, false-positive staining, or biallelic 
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somatic mutations (Haraldsdottir et al., 2014). Individuals with biallelic somatic mutations are 
considered unlikely to have LS because these cases are either caused by two somatic mutations or one 
somatic mutation combined with somatic loss of heterozygosity, thus resulting in MMR deficiency in the 
tumor (Buecher et al., 2018; Mesenkamp et al., 2014).Biallelic somatic MMR mutations may explain up 
to 52% of UMMRD, helping to inform LS status and potentially sparing patients and their families from 
intensive cancer screenings (Mensenkamp et al., 2014; Sourrouille et al., 2012). 
Biallelic somatic MMR mutations cannot be differentiated from LS using tumor pathology, MSI 
analysis, or IHC staining, so challenges arise when UMMRD occurs (Haraldsdottir et al., 2014; 
Hemminger et al., 2018). However, next-generation sequencing has led to more frequent utilization of 
tumor profiling to pinpoint somatic mutations (Hamepl et al., 2018; Pritchard et al., 2012; Varga et al., 
2015) and can be applied to LS tumors as an additional risk assessment tool.  
Even though there are opportunities to utilize somatic testing in the evaluation of LS, the 
corresponding guidelines have not caught up to the available technology. There is currently no consensus 
about the LS status of individuals with UMMRD (Batte, et al, 2013) and, somatic MMR testing does not 
explain all MSI-high tumors without a germline mutation. This creates dilemmas for genetic counselors 
and physicians in providing screening recommendations. Only 5.2% of genetic counselors have reported 
being “completely prepared” and 67% reported being “somewhat prepared” to handle comprehensive 
tumor profiling results (Goedde et al., 2017). However, it is still unknown how this applies to LS somatic 
MMR testing. The National Comprehensive Cancer Network (NCCN) current guidelines (NCCN, 
Version 1.2018) contain limited recommendations for the interpretation of somatic MMR testing for LS 
in a footnote (LS-A 4 of 5; footnote d). The footnote discusses biallelic somatic MMR mutations as a 
possible explanation for UMMRD and suggests genetic consultation for complex results without 
guidelines for interpreting complex results. This minimal guidance leaves room for inconsistency among 
genetic counseling practices.  
The availability of somatic MMR testing in evaluation of LS has great implications for patient 
management, but its use among cancer genetic counselors has not been studied. Thus, we aimed to 
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investigate current somatic MMR ordering practices, and consistency in risk assessments by cancer 
genetic counselors to identify gaps in available recommendations and assess the need for more 
comprehensive guidelines. 
 
METHODS 
This study was approved by the University of Texas Health Science Center Institutional Review Board, 
governed by the Committee for the Protection of Human Subjects (HSC-MS-18-0442). 
 
Participants and Procedures:  
Participants were recruited to this cross-sectional study through the National Society of Genetic 
Counselors (NSGC) listserv between September 2018 and November 2018. A survey link was sent via 
email to all NSGC registered members, followed by a reminder, and posted to the Cancer Special Interest 
Group (SIG) discussion board. Practicing board-certified or board-eligible clinical genetic counselors, 
who actively see patients in the cancer setting, were eligible to participate in the study. The survey was 
anonymous and remained open for 8 weeks. Informed consent was obtained prior to proceeding to the 
questionnaire portion of the survey. Participants were excluded from the study if they were employed by 
a diagnostic laboratory, did not meet the eligibility criteria, or only completed the demographic section 
of the survey.  
 
Instrumentation:  
Qualtrics (Qualtrics, Provo, UT) was used to administer the survey and collect data. Participants 
who consented to the study were asked eligibility criteria, demographic information, current ordering 
practices, scenarios involving hypothetical patients, and views on further guidelines. The subjects were 
given an opportunity for free-text comments at the end of the survey. The question format varied, with 
the vast majority (45/53 content questions) being multiple choice. Subjects could exit the survey at any 
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point, and subjects were not required to answer every question. The study questionnaire was created by 
the authors and was not externally validated (Appendix A). 
 
Data Analysis:  
Data was analyzed using STATA (version 13.1, College Station, TX) with a level of significance 
of p≤0.05. Descriptive statistics were completed including medians for continuous variables and 
frequencies and percentages for categorical variables. Demographic responses were compared to the 
results of the NSGC 2018 Professional Status Survey (PSS) using proportion tests. Chi-square, Fisher 
exact, and Wilcoxon rank-sum tests were used to compare differences between responses for selected 
questions and estimate the significance. Free responses were analyzed to identify themes within 
participant comments, with the flexibility to code multiple themes for one response. 
 
RESULTS 
Demographics: 
Following the survey closure, there were 224 total responses. Thirteen responses were excluded 
due to ineligibility, while 11 did not meet the minimum completeness requirement and were also 
excluded. The remaining 200 respondents were included in the study. Since participants were not 
required to answer every question, the total number of responses varied across questions. Demographic 
information is reported in Table 1. The majority of participants worked full-time (98%, n = 195/200), 
had less than six years of experience in a cancer setting (75%, n = 150/200), and did not practice 
additional specialties (69%, n = 137/200). Most individuals (86%, n = 171/200) worked with other 
genetic counselors. Just over half (52%, n = 103/198) of respondents practiced in a state with licensure. 
The median number of colorectal cancer cases assessed per month (personal or family history) was five 
(Interquartile range: 4-10) and the median number of uterine cancer cases assessed per month (personal 
or family history) was three (Interquartile range: 2-5). Demographics were compared to the 2018 NSGC 
PSS and did not reveal any statistically significant differences for licensure status or regions 1-5. Region 
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6 was underrepresented in our responses compared to the PSS. While different work setting options were 
presented in the two surveys, there were no statistically significant differences for the proportion of 
individuals at a university medical center or in a private medical facility. However, there were a higher 
proportion of genetic counselors who worked at a public medical facility in our cohort compared to the 
PSS. 
 
Table 1. Participant demographics 
  
All (n=200) 
n (%) 
Academic Setting 
p-
value 
Sole GC 
p-
value 
    
Yes 
(n=110) 
No 
(n=90) 
Yes 
(n=29) 
No 
(n=171) 
Experience in Cancer     0.562    0.697 
   0-5 years 150 (75) 84 (42) 66 (33)  20 (10) 130  
   6-10 years 28 (14) 15 (7.5) 13 (6.5)  6 (3) 22 (11)  
   11-15 years 9 (4.5) 6 (3) 3 (1.5)  1 (0.5) 8 (4)  
   16-20 years 8 (4) 4 (2) 4 (2)  1 (0.5) 7 (3.5)  
   >20 years 5 (2.5) 1 (0.5) 4 (2)  1 (0.5) 4 (2)  
Position Type     0.176    0.154 
   Full-time (>30 hr/wk) 195 (97.5) 109 (54.5) 86 (43)  27 (13.5) 168 (84)  
   Part-time (<30 hr/wk) 5 (2.5) 1 (0.5) 4 (2)  2 (1) 3 (1.5)  
Setting *          
   Public 70 (35) 28 (14) 42 (21) 0.002 17 (8.5) 53 (26.5) 0.004 
   Private 53 (26.5) 13 (6.5) 40 (20) <0.001 10 (5) 43 (21.5) 0.292 
   University 83 (41.5) 81 (40.5) 2 (1) <0.001 0 (0) 83 (41.5) <0.001 
   Physician’s practice 4 (2) 0 (0) 4 (2) 0.040 2 (1) 2 (1) 0.101 
   Other 5 (2.5) 1 (0.5) 4 (2) 0.176 0 (0) 5 (2.5) 1.000 
Additional Specialties          
   Only cancer cases 137 (68.5) 78 (39) 59 (29.5) 0.417 22 (11) 115 (57.5) 0.356 
   Other specialties*          
     General genetics 31 (15.5) 20 (10) 11 (5.5) 0.247 3 (1.5) 28 (14) 0.581 
     Pediatrics 27 (13.5) 16 (8) 11 (5.5) 0.632 2 (1) 25 (12.5) 0.381 
     Adult 37 (18.5) 19 (9.5) 18 (9) 0.621 2 (1) 35 (17.5) 0.118 
     Cardiology 22 (11) 8 (4) 14 (7) 0.063 2 (1) 20 (10) 0.747 
     Neurogenetics 11 (5.5) 3 (1.5) 8 (4) 0.068 1 (0.5) 10 (5) 1.000 
     Metabolic 3 (1.5) 2 (1) 1 (0.5) 1.000 0 (0) 3 (1.5) 1.000 
     Prenatal 23 (11.5) 7 (3.5) 16 (8) 0.012 3 (1.5) 20 (10) 1.000 
     Other 7 (3.5) 4 (2) 3 (1.5) 1.000 1 (0.5) 6 (3) 1.000 
Cancer Subspecialty           
   None 184 (92) 97 (48.5) 87 (43.5) 0.035 27 157 1.000 
   Subspecialty * 16 (8)         
     Breast 5 (2.5) 4 (2) 1 (0.5) 0.381 1 (0.5) 4 (2) 0.547 
     Gynecological 5 (2.5) 3 (1.5) 2 (1) 1.000 2 (1) 3 (1.5) 0.154 
     Gastrointestinal 9 (4.5) 7 (3.5) 2 (1) 0.190 2 (1) 7 (3.5) 0.621 
     Genitourinary 2 (1) 1 (0.5) 1 (0.5) 1.000 1 (0.5) 1 (0.5) 0.27 
     Pediatric 3 (1.5) 2 (1) 1 (0.5) 1.000 0 (0) 3 (1.5) 1.000 
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     Other 3 (1.5) 3 (1.5) 0 (0) 0.254 0 (0) 3 (1.5) 1.000 
NSGC Region **     0.099    0.338 
   Region 1 16 (8) 14 (7) 2 (1)  0 (0) 16 (8)  
   Region 2 48 (24) 24 (12) 24 (12)  9 (4.5) 39 (19.5)  
   Region 3 21 (11) 10 (5) 11 (5.5)  3 (1.5) 19 (9.5)  
   Region 4 62 (31) 34 (17) 28 (14)  12 (6) 50 (25)  
   Region 5 32 (16) 19 (9.5) 13 (6.5)  3 (1.5) 29 (14.5)  
   Region 6 20 (10) 9 (4.5) 11 (5.5)  2 (1) 18 (9)  
                  
* Subcategories are not mutually exclusive     
** Region 1 (CT, MA, ME, NH, RI, VT, CN Maritime Provinces)    
 Region 2 (DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI Quebec)    
 Region 3 (AL, FL, GA, KY, LA, MS, NC, SC, TN)     
 Region 4 (AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, Ontario)   
 Region 5 (AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Sask)   
 Region 6 (AK, CA, HI, ID, NV, OR, WA, British Columbia)    
 
Ordering Practices: 
Participants were asked about their institution’s ordering practices for IHC, MSI, and somatic 
MMR testing in the work-up for LS. These responses are reported in Table 2. Most individuals (91%, n = 
181/200) reported their institution included IHC and the majority of those (85%, n = 154/181) used an 
in-house laboratory. Less than half (44%, n = 87/199) worked at an institution that included MSI in the 
LS work-up, with the majority of these (74%, n = 64/87) performed at an in-house laboratory. Genetic 
counselors who worked in an academic setting were more likely to have an institution that used an in-
house laboratory for both IHC (p = 0.003) and MSI (p < 0.0001) testing than those not at an academic 
institution. Less than a third (29%, n = 57/199) of respondents reported their institution included somatic 
MMR testing in evaluation of LS, with the majority (66%, n = 37/56) performed at an external 
laboratory. Of those who had experience ordering somatic MMR testing, less than a quarter (23%, n = 
28/124) reported “routinely” ordering this testing and half (50%, n = 62/124) reported only using this 
testing “occasionally” or “rarely”. 
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Table 2. Description of ordering practices 
  All 
(n=200) 
n (%) 
Academic Setting 
p-
value 
Sole GC 
p-
value 
    
Yes 
(n=110) 
No 
(n=90) 
Yes 
(n=29) No (n=171) 
IHC work-up     0.634    0.646 
   Included 181 (91) 101 (51) 80 (40)  27 (14) 154 (77)  
   Not included 14 (7) 6 (3) 8 (4)  2 (1) 12 (6)  
   Unsure 5 (2) 3 (1) 2 (1)  0 (0) 5 (2)  
IHC testing^     0.003    0.433 
   In-house 154 (86) 93 (52) 61 (34)  24 (13) 130 (72)  
   Send-out 16 (9) 3 (2) 13 (7)  3 (2) 13 (7)  
   Unsure 10 (5) 4 (2) 6 (3)  0 (0) 10 (6)  
MSI work-up     0.185    0.770 
   Included 87 (44) 54 (27) 33 (17)  12 (6) 75 (37)  
   Not included 99 (50) 49 (25) 50 (25)  16 (8) 83 (42)  
   Unsure 13 (6) 6 (3) 7 (3)  1 (1) 12 (6)  
MSI testing^     <0.001    <0.001 
   In-house 64 (74) 49 (56) 15 (17)  3 (3) 61 (70)  
   Send-out 17 (19) 3 (4) 14 (16)  7 (8) 10 (12)  
   Unsure 6 (7) 2 (2) 4 (5)  2 (2) 4 (5)  
MMR work-up     0.867    0.584 
   Included 57 (29) 32 (16) 25 (13)  7 (3) 50 (25)  
   Not included 127 (64) 68 (34) 59 (30)  21 (11) 106 (53)  
   Unsure 15 (7) 9 (4) 6 (3)  1 (1) 14  (7)  
MMR testing^     0.116    0.803 
   In-house 15 (27) 12 (21) 3 (5)  1 (2) 14 (25)  
   Send-out 37 (66) 18 (32) 19 (34)  6 (11) 31 (55)  
   Unsure 4 (7) 2 (4) 2 (4)  0 (0) 4 (7)  
Tumor Profiling 
Experience     0.949    0.025 
   Yes 165 (83) 91 (46) 74 (37)  20 (10) 145 (72)  
   No 33 (17) 18 (9) 15 (8)  9 (4) 24 (12)  
Tumor Profiling Comfort     0.659    0.004 
   Extremely comf. 22 (11) 14 (7) 8 (4)  2 (1) 20 (10)  
   Somewhat comf. 100 (51) 57 (29) 43 (22)  8 (4) 92 (46)  
   Neutral 31 (16) 16 (8) 15 (8)  9 (5) 22 (11)  
   Somewhat uncomf. 38 (19) 19 (9.5) 19 (9.5)  7 (4) 31 (15)  
   Extremely uncomf. 6 (3) 2 (1) 4 (2)  3 (2) 3 (2)  
Somatic MMR experience     0.385    0.415 
   Yes 161 (81) 91 (46) 70 (35)  22 (11) 139 (70)  
   No 37 (19) 18 (9) 19 (10)  7 (4) 30 (15)  
Somatic MMR comfort     0.134    0.007 
   Extremely comf. 73 (37) 44 (23) 29 (15)  8 (6) 65 (45)  
   Somewhat comf. 93 (48) 53 (27) 40 (20)  11 (8) 30 (21)  
   Neutral 15 (8) 6 (3) 9 (5)  3 (2) 12 (8)  
   Somewhat uncomf. 12 (6) 4 (2) 8 (4)  6 (4) 6 (4)  
   Extremely uncomf. 2 (1) 0 (0) 2 (1)  1 (1) 1 (1)  
MMR impacts assessment     0.041    0.069 
   Always 46 (29) 29 (18) 17 (11)  4 (3) 42 (26)  
   Usually 71 (45) 44 (28) 27 (17)  7 (4) 64 (40)  
   Sometimes 29 (18) 10 (6) 19 (12)  9 (6) 20 (12)  
   Rarely 10 (6) 5 (3) 5 (3)  1 (1) 9 (6)  
   Never 3 (2) 3 (2) 0 (0)  0 (0) 3 (2)  
Experience/perceive 
barriers     0.534    0.029 
   Yes 149 (77) 84 (43) 65 (34)  17 (9) 132 (68)  
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   No 45 (23) 23 (12) 22 (11)  11 (5) 34 (18)  
Barriers**          
   Cost 102 (51) 60 (30) 42 (21) 0.267 15 (8) 87 (44) 0.933 
   Coordinating tissue 99 (50) 52 (26) 47 (24) 0.486 10 (5) 89 (45) 0.080 
   Lack of institution support 35 (18) 19 (10) 16 (8) 0.925 7 (4) 28 (14) 0.309 
   Unsure how to interpret 12 (6) 7 (4) 5 (3) 0.811 2 (1) 10 (5) 0.687 
   Lack of time 17 (9) 12 (6) 5 (3) 0.177 3 (2) 14 (7) 0.718 
   Not available in-house 46 (23) 32 (16) 14 (7) 0.024 8 (4) 38 (19) 0.633 
   Not offered by preferred 
lab 38 (19) 26 (13) 12 (6) 0.065 6 (3) 32 (16) 0.800 
   Other 34 (17) 20 (10) 14 (7) 0.579 2 (1) 32 (16) 0.298 
      Insurance/billing issues* 9 (5) 6 (3) 3 (2) 0.518 0(0) 9(5) 0.362 
      Limited tissue* 6 (3) 4(2) 2(1) 0.692 0(0) 6(3) 0.596 
      Turnaround time* 7 (4) 3 (2) 4 (2) 0.703 0 (0) 7(4) 0.596 
* Themes from text responses Uncomf. = uncomfortable  
^ Only includes 'yes' responses from previous category Comf. = comfortable 
** Subcategories not mutually exclusive     
 
The survey also investigated genetic counselor experience and comfort level with both tumor 
profiling and somatic MMR testing. Most individuals (83%, n = 165/198) had experience with tumor 
profiling results (such as those obtained from external vendors such as FoundationOne) and the majority 
(62%, n = 122/197) reported they felt “somewhat comfortable” or “extremely comfortable” interpreting 
these types of results. The majority of respondents (81%, n = 161/198) had experience reviewing somatic 
MMR testing results, with nearly three-quarters (73%, n = 117/159) of those results “usually 
contributing” or “always contributing” to the risk assessment of LS cases. When participants were asked 
if they do or would feel comfortable interpreting somatic MMR results, 85% (n = 166/195) reported they 
felt “somewhat comfortable” or “extremely comfortable”. 
Over three-quarters (76.8%, n = 149/194) of respondents experienced or perceived barriers to 
ordering somatic MMR testing, with cost and coordinating tissue samples being the most frequently 
cited. The reported barriers are summarized in Figure 1. Genetic counselors at an academic institution 
were more likely (p = 0.024) to cite lack of in-house availability as a barrier to somatic MMR testing 
compared to those not at an academic institution. Those who work with other cancer genetic counselors 
were more likely to experience or perceive barriers to somatic MMR testing than those who were the 
sole cancer genetic counselor at their institution (p = 0.029). 
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Figure 1. Perceived barriers by participants to somatic MMR testing 
 
*Categories not mutually exclusive    ^Themes coded from free-text responses 
 
Scenario-based Questions: 
During the scenario portion of the survey, participants were given four different theoretical 
scenarios created by the authors with information about a hypothetical patient’s diagnosis and tumor 
staining results in addition to a pedigree. Question topics included the likelihood of the patient having LS 
(before and after learning the patient’s somatic MMR results), the next recommended step in the genetics 
evaluation, and screening recommendations for the patient and first-degree relatives. The pedigrees for 
these scenarios are displayed in Figure 2. 
Scenario 1 (Figure 2: A) involved a 67-year old male with colorectal cancer that had loss of 
staining in MLH1 and PMS2 with negative MLH1 promoter methylation and BRAF mutation analysis. 
This patient was later revealed to have biallelic somatic mutations in MLH1 with negative germline 
testing. Scenario 2 (Figure 2: B) was a 23-year old female with colorectal cancer and a noncontributory 
family history. Tumor testing showed loss of staining in MSH2 and MSH6. Somatic testing showed 
biallelic somatic mutations in MSH2 and germline testing was negative. Scenario 3 (Figure 2: C) showed 
a 46-year old female with uterine cancer and family history meeting Amsterdam criteria. The tumor IHC 
results were loss of staining in MSH2 and MSH6. Participants were later informed her somatic testing 
51%
50%
18%
6%
9%
23%
19%
6% 5% 4% 3%
0% 10% 20% 30% 40% 50% 60%
Other
Cost
Coordinating Tissue
Lack of Institution Support
Unsure of Interpretation
Lack of Time
Not Available In-house
Not Offered by Preferred Lab
Other Insurance/billing^ Turnaround time^ Limited tissue^
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showed a monoallelic mutation in MSH2 with negative germline testing. Scenario 4 (Figure 2: D) 
involved a 62-year old male with colorectal cancer and loss of staining in MLH1 and PMS2 with 
negative MLH1 promoter methylation and BRAF mutation analysis. His family history was 
noncontributory, although his unaffected father died at age 52. Both the somatic and germline testing 
results were negative. 
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Figure 2. Scenario pedigrees (A-D) provided to participants. 
A
 
 
B
 
 
C
 
 
 
 
D
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For all scenarios, the majority (52-59%) of participants indicated their next step would have been 
concurrent germline and somatic testing that included the MMR genes. For the scenarios involving 
biallelic somatic mutations, the initial likelihood for LS was mostly ranked as “unlikely” (scenario 1; 
79%, n = 152/192) or “highly likely” (scenario 2; 82%, n = 155/190). After learning the somatic testing 
results for these scenarios, the majority (77%, n = 148/192; 89%, n = 169/190 for scenario 1 and 2, 
respectively) of respondents shifted to a lower LS likelihood of either “unlikely” or “definitely not”. For 
the scenario regarding monoallelic somatic mutations (scenario 3), most participants indicated “highly 
likely” before (88%, n = 165/187) and after (75%, n = 139/186) knowing the patient’s somatic results, 
with most (71%, n = 133/186) individuals selecting the same likelihood for both questions. Scenario 4 
involved a patient with negative somatic and germline results, with most (59%, n = 105/177) individuals 
ranking the likelihood for LS as “unlikely” for both risk assessment questions and approximately a 
quarter (28%, n = 50/177) downgrading their LS suspicion. Most individuals recommended LS screening 
for the patient (81%, n = 149/185) with monoallelic somatic mutations (scenario 3) and her first-degree 
relatives (68%, n = 128/187). For the other three scenarios, the majority screening recommendation was 
“population-level” for the proband (48-66%) and “early colonoscopy based on family history” for the 
first-degree relatives (56-90%). The scenario responses are summarized in Table 3. 
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Table 3. Participant responses to scenario questions 
 
 Scenario 1 Scenario 2 Scenario 3 Scenario 4 
  
Patient 
67-year old male 
(colorectal cx). 
Loss of 
MLH1/PMS2**. 
Neg family hx. 
23-year old 
female (colorectal 
cx). Loss of 
MSH2/MSH6. 
Neg family hx. 
46-year old female 
(uterine cx). Loss 
of MSH2/MSH6. 
Meets Amsterdam. 
62-year old male 
(colorectal cx). 
Loss of 
MLH1/PMS2**. 
Neg family hx. 
  Pedigree B C D E 
  
Somatic Results 
*Biallelic MLH1 
somatic mut. 
Germline neg. 
*Biallelic MSH2 
somatic mut. 
Germline neg. 
*Monoallelic 
MSH2 somatic 
mut. Germline 
neg. 
*Somatic & 
germline 
negative. 
   n (%) n (%) n (%) n (%) 
Q1. Lynch Likelihood         
   Absolutely 0 (0) 0 (0) 20 (11) 0 (0) 
   Highly likely 40 (21) 155 (82) 165 (88) 25 (14) 
   Unlikely 152 (79) 35 (18) 2 (1) 151 (85) 
   Definitely not 0 (0) 0 (0) 0 (0) 2 (1) 
Q2. Next step         
   Germline 52 (27) 48 (25) 56 (30) 43 (24) 
   Germline reflex somatic 19 (10) 35 (18) 32 (17) 18 (10) 
   Germline + somatic 114 (59) 102 (54) 98 (52) 106 (59) 
   No further eval. 3 (2) 0 (0) 0 (0) 8 (5) 
   Other 4 (2) 5 (3) 1 (1) 4 (2) 
Q3. *Lynch likelihood         
   Absolutely 0 (0) 1 (1) 9 (5) 0 (0) 
   Highly likely 3 (2) 4 (2) 139 (75) 13 (7) 
   Unlikely 60 (31) 107 (56) 35 (19) 121 (68) 
   Definitely not 129 (67) 78 (41) 3 (1) 44 (25) 
Q4. Proband screening         
   Population 127 (66) 90 (48) 10 (5) 105 (59) 
   Lynch 6 (3) 13 (7) 149 (81) 18 (10) 
   Other 59 (31) 86 (45) 26 (14) 54 (31) 
      Personal hx 42 (22) 56 (30) 14 (8) 26 (15) 
Q5. FDR screening         
   Population 56 (29) 5 (3) 0 (0) 52 (29) 
   Family hx 122 (64) 172 (90) 45 (24) 100 (56) 
   Lynch 0 (0) 3 (2) 128 (68) 12 (7) 
   Other 13 (7) 10 (5) 14 (8) 14 (8) 
Key    
    
* Somatic test results provided after Q2   
** Negative MLH1 methylation and BRAF mutation analysis   
 
Further Guidelines and Comments: 
When asked if additional, more specific, national guidelines for the ordering and/or 
interpretation of MMR somatic testing would be beneficial, 77% (n=140) of respondents answered ‘yes’ 
and 17% (n=31) responded ‘maybe’. 
At the conclusion of the survey, participants were given an opportunity to provide additional 
comments in a free-text format. Select comments are displayed in Table 4. While extensive patterns in 
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the comment section did not emerge, a few individuals confirmed further guidelines would be helpful. A 
few others also reiterated that in their experiences, concurrent germline and somatic testing was 
beneficial for billing purposes. None of the comments provided explanations for individuals who 
indicated they did not feel further guidelines would be helpful. 
 
Table 4. Free response examples 
Theme Example Comment 
 
Barriers to 
Somatic Testing 
 
“While we may want to start with germline and then reflex to somatic (in 
some cases)… there is better coverage to order concurrently; so while it 
may not clinically be the best way to order testing, it is financially better for 
our patients.” 
 
“Turnaround time is also a contributing factor… I would sacrifice somatic 
results for germline results in those cases where surgical decision making 
regarding Lynch syndrome are reliant upon results...” 
 
Further 
Guidelines 
“Our clinic is getting more and more questions from oncologists at our 
institution regarding tumor testing for Lynch and other conditions. National 
guidelines for tumor testing in general would be extremely beneficial for 
cancer genetic counseling.” 
 
“Additional information on interpretation of MMR somatic tumor testing 
would be extremely beneficial. A lot has been learning as I go and I am not 
sure I am doing that great of a job at it…” 
 
Screening 
Recommendations 
“We make guideline recommendations based on the NCCN guidelines.  In 
some situations, we may encourage more high risk screening methods… 
but we defer to the patient's supervising physician…” 
 
“For those with abnormal results and no informative germline/somatic 
results there is no clear cut recommendations and every family needs to be 
looked at individual and notes should include limitations to our knowledge 
and any recommendations.” 
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DISCUSSION 
Cancer genetic counselors currently have several tools available to assess an individual’s risk of 
LS, including IHC staining, MSI analysis, somatic MMR testing, and germline testing. While not all of 
these tools may be indicated in every case, UMMRD cases may require more extensive testing to 
accurately determine LS status and ultimately screening recommendations for patients and their relatives. 
Given the importance of appropriate patient management, this study surveyed two hundred currently-
practicing cancer genetic counselors regarding their current ordering practices and interpretation of 
somatic MMR results in the context of a hypothetical LS case to evaluate the sufficiency of current 
national guidelines. The results of this survey demonstrate cancer genetic counselors’ acknowledged 
importance of somatic MMR testing in theoretical practice and in past instances, despite a scarcity of 
routine inclusion in real-world ordering practices. 
Cancer genetic counselors seem to be largely aware of the benefits of somatic MMR testing and 
demonstrate interest in ordering it for their patients. Participants with past experience utilizing somatic 
MMR testing indicated the positive impact these results had on risk assessment. This sentiment was also 
reflected in the hypothetical scenarios, as a majority of participants indicated they would consider 
somatic MMR testing in conjunction with germline testing as the ideal next step in their LS evaluation. 
Previous literature has shown that patients also tend to positively view tumor screening for LS and 
understand its benefits (Hunter et al., 2015).  
Despite genetic counselor understanding of its benefits, somatic MMR testing was rarely 
included in the respondents’ current institution ordering practices for LS work-up. While most 
respondents had previous experience ordering somatic MMR testing and reported feeling at least 
“somewhat comfortable” with interpreting these results, only a small minority reported routinely 
ordering this testing. The discrepancy between ideal and current testing practices illustrates a gap, 
perhaps related to barriers to testing.  
In fact, a high frequency of genetic counselors reported encountering or perceiving barriers to 
ordering somatic MMR testing. The most common reported barriers included cost, coordinating tissue 
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samples, and lack of in-house availability, with lack of knowledge regarding result interpretation among 
the least frequently cited. Many individuals reported additional barriers in the free-text response, with 
themes emerging in billing/insurance issues, long turnaround time, and lack of tumor tissue. Since these 
themes were individually reported as free-text responses and not displayed as options to all participants, 
these barriers may be underrepresented in this study. Previous literature regarding ordering tumor 
profiling found each of these three barriers to be reported in more than 70% of their participants 
(Kurzrock et al., 2015), which may be similar in somatic MMR testing. 
Interestingly, genetic counselors who were the sole genetic counselor at their institution were 
less likely to report experiencing these barriers. This may be an indication that sole genetic counselors 
are viewed to have slightly different scopes of practice or perhaps reflects a difference in clinic structure 
or institution size. 
The vast majority of participants reported that additional, more specific, national guidelines 
surrounding somatic MMR testing would be beneficial to their practice. The NCCN current guidelines 
(NCCN, Version 1.2018) includes limited recommendations for the interpretation of somatic MMR 
testing in the form of a footnote (LS-A 4 of 5; footnote d). This footnote cites evidence supporting 
biallelic somatic MMR mutations as an explanation for UMMRD, therefore tumor sequencing may assist 
in clarifying the result. It discusses that in cases with monoallelic somatic mutations, the unidentified 
mutation could be germline or somatic. However, the guidelines state family history-based management 
should be used regardless of somatic testing results. The footnote also suggests genetic consultation for 
complex results but doesn’t provide guidelines for interpreting those results. While there are mentions of 
somatic MMR testing in national guidelines, it does not encompass all possible scenarios, and is not 
nearly as extensive as guidelines for germline testing.  The creation of clear guidelines may further 
increase genetic counselor comfort with ordering somatic MMR testing and encourage them to seek out 
this testing more often, thereby enhancing patient management. Since some insurance companies use 
national guidelines to determine coverage criteria, this may also reduce insurance and billing issues. 
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Study limitations: 
This study population may reflect a self-selecting bias in which those genetic counselors with 
experience or interest in somatic MMR testing may have been more likely to complete the survey than 
those with more limited knowledge. In addition, the questionnaire was created by the authors and has not 
been formally validated. While most participant characteristics were not significantly different between 
this study and the PSS, including licensure and regions 1-5, this study may have had a higher proportion 
of genetic counselors who worked at a public medical facility and a lower proportion of genetic 
counselors in region 6, which could have created a skewed sample. However, the work setting 
differences may simply be a reflection of different answer choices included on this survey compared to 
those of the PSS. Additionally, the NCCN guidelines underwent revisions within a few months of survey 
distribution which changed recommendations for those with monoallelic somatic mutations from LS 
screening to family history-based screening. Therefore, individuals may have made recommendations for 
LS screening as a reflection of prior guidelines. 
 Of note, for three of the scenario questions, it was observed that a majority of participants chose 
“population-level screening” for a proband affected with cancer. However, individuals with a history of 
cancer generally require additional screening compared to the general population in order to monitor for 
disease recurrence. Therefore, this survey response may represent an artifact of the survey structure or 
wording for this specific question. While the authors intended this to represent typical post-cancer 
screening protocols, this phrase may have been interpreted differently by respondents. Given the only 
other provided response was LS screening, this option may have been understood as non-LS screening or 
as typical screening for the colon/uterine cancer population. Therefore, conclusions could not be drawn 
regarding these responses. 
 
Practice Implications: 
This study provides insights into the ordering practices of cancer genetic counselors in 
evaluating for LS, interpretations of somatic MMR testing, and barriers to this testing. Since many of the 
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reported barriers involved lab-related issues rather than knowledge, it may be beneficial for genetic 
counselors to advocate for different lab billing practices or in-house somatic MMR testing to ensure this 
option is available, especially for UMMRD cases. 
While many genetic counselors reported some level of comfort with interpreting somatic MMR 
testing results, further guidelines may allow for further consensus, higher comfort levels, and portray 
benefit to insurance companies. This may provide genetic counselors with more guideline resources, 
confidence in their abilities to interpret somatic MMR testing, and leverage when advocating for this 
testing option. Further guidelines may also reflect larger consensus and wider acceptance as a risk 
assessment tool, which may aid in lowering costs and improving insurance coverage. 
 
Research Recommendations: 
Further studies investigating the barriers to somatic MMR testing may be beneficial in 
determining strategies for eliminating or reducing those barriers. These potential studies could also 
explore and confirm the differences between sole genetic counselors and those who work along with 
other genetic counselors in terms of ordering practices, comfort with somatic testing, and likelihood to 
report barriers to somatic MMR testing. Advancements in genetic knowledge and cancer technologies 
may create other avenues for LS risk assessment or reveal other explanations for UMMRD, which may 
alter ordering practices. Future research could compare ordering practices over time to find other factors 
contributing to the rate of testing uptake and accessibility of new testing options.  
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APPENDIX 
 
Appendix A. Complete survey of this study 
Start of Block: Consent 
Q1 You are invited to take part in a research study called, “Genetic Counselor Utilization and 
Interpretation of Somatic Tumor Testing for Lynch Syndrome”, conducted by Danielle Williams, of 
The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical 
Sciences. 
 
The purpose of this study is to describe current clinical practice among genetic counselors seeing cancer 
patients for evaluation of Lynch syndrome. All board-certified or board-eligible genetic counselors who 
see cancer patients are invited to participate, regardless of exposure to somatic tumor testing. 
 
If you consent to take part in this study you will complete a 15-20 minute survey via the online survey 
tool, Qualtrics. All survey submissions will be anonymous.   
 
The information you provide will help us better understand current clinical practices of cancer genetic 
counselors evaluating patients for Lynch syndrome. You may not receive any direct benefit from taking 
part in this study. The only possible risk may be breach of confidentiality; the information collected will 
not contain identifying information. You have the alternative to choose to not take part in this study and 
may withdraw at any time.  
 
There is no cost and you will not be paid to take part in this study. You will not be personally identified 
in any reports or publications that may result from this study.  Any personal information about you that is 
gathered during this study will remain confidential to every extent of the law.    
 
This research project has been reviewed by the Committee for the Protection of Human Subjects (CPHS) 
of the University of Texas Health Science Center at Houston (HSC-MS-18-0442). For any questions 
about research subjects rights call CPHS at (713) 500-7943. This study is being conducted by M.S. 
Candidate Danielle Williams under the direction of Maureen Mork, M.S., C.G.C. Should you have any 
questions, please feel free to contact either at danielle.williams@uth.tmc.edu or 
memork@mdanderson.org. 
o I have read the consent and agree to take part in the study  (1)  
o I do not provide my consent and/or do not wish to take part in the study  (2)  
Skip To: End of Survey If You are invited to take part in a research study called, “Genetic Counselor 
Utilization and Inter... = I do not provide my consent and/or do not wish to take part in the study 
Start of Block: Qualification Questions 
Q2 Are you a currently practicing, board certified or board eligible, genetic counselor who sees patients 
for evaluation of hereditary cancer? 
o Yes  (1)  
o No  (2)  
Skip To: End of Survey If Are you a currently practicing, board certified or board eligible, genetic 
counselor who sees pat... = No 
Q3 Do you work in a clinical or non-clinical setting? 
o I am a clinical counselor and counsel patients as a regular part of my job  (1)  
o I am a non-clinical counselor and typically do not counsel patients  (2)  
Skip To: End of Survey If Do you work in a clinical or non-clinical setting? = I am a non-clinical 
counselor and typically do not counsel patients 
Start of Block: Demographics 
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Q4 For how many years have you been seeing patients for evaluation of hereditary cancer? 
o 0-5 years  (1)  
o 6-10 years  (2)  
o 11-15 years  (3)  
o 16-20 years  (4)  
o 20+ years  (5)  
 
Q5 Do you work as a genetic counselor full-time or part-time? 
o Part-time (1)  
o Full-time (>30 hours per week)  (2)  
 
Q6 What type of setting do you work in? Select all that apply 
▢ Public hospital/medical facility  (1)  
▢ Private hospital/medical facility  (2)  
▢ University Medical Center  (3)  
▢ Physician’s private practice  (4)  
▢ Diagnostic laboratory  (5)  
▢ Other  (6) ________________________________________________ 
Display This Question: If What type of setting do you work in? Select all that apply = Diagnostic 
laboratory 
Q7 Does your employer offer somatic MMR testing? (Haraldsdottir et al., 2014; Mensenkamp et al., 
2014; NCCN, Version 3.2017) 
o Yes  (1)  
o No  (2)  
Skip To: End of Survey If Does your employer offer somatic MMR testing?... = No 
Q8 Do you consider your workplace to be an academic or non-academic institution? 
o Academic  (1)  
o Non-academic  (2)  
Q9 Do you exclusively see cancer cases? 
o Yes  (1)  
o No, I see other specialties as well (2)  
Display This Question: If Do you exclusively see cancer cases? = No, I see other specialties as well 
Q10 What other specialties do you see? Select all that apply 
▢ General genetics  (1)  
▢ Pediatrics  (2)  
▢ Adult genetics  (3)  
▢ Cardiology  (4)  
▢ Neurogenetics  (5)  
▢ Metabolic diseases  (6)  
▢ Prenatal  (7)  
▢ Other  (8) ________________________________________________ 
Q11 Do you specialize in a certain domain within the cancer setting? 
o Yes  (1)  
21 
 
o No, I practice in a general cancer genetics setting  (2)  
Display This Question: If Do you specialize in a certain domain within the cancer setting? = Yes 
Q12 Which cancer domain do you specialize in? Select all that apply 
▢ Breast  (1)  
▢ Gynecological  (2)  
▢ Gastrointestinal (GI)  (3)  
▢ Genitourinary (GU)  (4)  
▢ Endocrine  (5)  
▢ Dermatology  (6)  
▢ Pediatric  (7)  
▢ Other  (8) ________________________________________________ 
 
Q13 Do you work with other cancer genetic counselors? 
o Yes, I work with other cancer genetic counselors  (1)  
o No, I am the only cancer genetic counselor at my institution  (2)  
 
Q14 In which region do you currently practice? 
o Region 1 (CT, MA, ME, NH, RI, VT, CN Maritime Provinces)  (1)  
o Region 2 (DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec)  (2)  
o Region 3 (AL, FL, GA, KY, LA, MS, NC, SC, TN)  (3)  
o Region 4 (AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, Ontario)  (4)  
o Region 5 (AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Sask)  (5)  
o Region 6 (AK, CA, HI, ID, NV, OR, WA, British Columbia)  (6)  
 
Q15 Does your state/province currently have licensure? 
o Yes  (1)  
o No  (2)  
Start of Block: Current practices 
Q16 About how many cases (personal or family history) do you see per month for colorectal cancer? 
 
Q17 About how many cases (personal or family history) do you see per month for uterine cancer? 
 
Q18 Does your institution include immunohistochemistry (IHC) tumor staining in the work-up for Lynch 
syndrome? 
o Yes  (1)  
o No  (2)  
o Unsure  (3)  
Display This Question: If Does your institution include immunohistochemistry (IHC) tumor staining in 
the work-up for Lynch... = Yes 
Q19 Is IHC testing performed in-house or through a send-out laboratory? 
o In-house  (1)  
o Send-out  (2)  
o Unsure  (3)  
 
Q20 Does your institution include microsatellite instability (MSI) testing in the work-up for Lynch 
syndrome? 
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o Yes  (1)  
o No  (2)  
o Unsure  (3)  
Display This Question: If Does your institution include microsatellite instability (MSI) testing in the 
work-up for Lynch s... = Yes 
Q21 Is MSI testing performed in-house or through a send-out laboratory? 
o In-house  (1)  
o Send-out  (2)  
o Unsure  (3)  
 
Q22 Does your institution include somatic tumor testing of the mismatch repair (MMR) genes in the 
work-up for Lynch syndrome? (Haraldsdottir et al., 2014; Mensenkamp et al., 2014; NCCN, Version 
3.2017) 
o Yes  (1)  
o No  (2)  
o Unsure  (3)  
Display This Question: If Does your institution include somatic tumor testing of the mismatch repair 
(MMR) genes in the wor... = Yes 
Q23 Is MMR somatic tumor testing performed in-house or through a send-out laboratory? 
o In-house  (1)  
o Send-out  (2)  
o Unsure  (3)  
 
Q24 Do you have experience with tumor profiling testing results (FoundationOne)? 
o Yes  (1)  
o No  (2)  
 
Q25 How comfortable do you feel interpreting tumor profiling results (FoundationOne)? 
o Extremely comfortable  (1)  
o Somewhat comfortable  (2)  
o Neither comfortable nor uncomfortable  (3)  
o Somewhat uncomfortable  (4)  
o Extremely uncomfortable  (5)  
 
Q26 Have you ever ordered and/or coordinated somatic tumor testing of the MMR genes in evaluation of 
Lynch syndrome? 
o Yes  (1)  
o No  (2)  
Display This Question: If Have you ever ordered and/or coordinated somatic tumor testing of the MMR 
genes in evaluation of... = Yes 
Q27 Have you ever ordered and/or coordinated somatic testing of the MMR in evaluation of Lynch 
syndrome for a colon tumor? 
o Yes  (1)  
o No  (2)  
Display This Question: If Have you ever ordered and/or coordinated somatic tumor testing of the MMR 
genes in evaluation of... = Yes 
Q28 Have you ever ordered and/or coordinated somatic testing of the MMR genes in evaluation of 
Lynch syndrome for a uterine tumor? 
o Yes  (1)  
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o No  (2)  
Display This Question: If Have you ever ordered and/or coordinated somatic tumor testing of the MMR 
genes in evaluation of... = Yes 
Q29 Is somatic MMR testing utilized when are evaluating a patient for Lynch syndrome? 
o Rarely (  (1)  
o Occasionally (10-30% of the time)  (2)  
o Often (30-80% of the time)  (3)  
o Routinely (>80% of the time)  (4)  
 
Q30 Have you ever reviewed/interpreted colon or uterine MMR somatic tumor testing results? 
o Yes  (1)  
o No  (2)  
Display This Question: If Have you ever reviewed/interpreted colon or uterine MMR somatic tumor 
testing results? = Yes 
Q31 In the cases where you have reviewed/interpreted somatic MMR tumor testing results, did those 
results contribute to your Lynch syndrome risk assessment? 
o Always (100% of the time)  (1)  
o Usually (70-99% of the time)  (2)  
o Sometimes (30-70% of the time)  (3)  
o Rarely (1-30% of the time)  (4)  
o Never (0% of the time)  (5)  
Display This Question: If Have you ever reviewed/interpreted colon or uterine MMR somatic tumor 
testing results? = No 
Q32 What are the reasons that contribute to not reviewing/interpreting colon or uterine MMR somatic 
tumor testing results? Select all that apply 
▢ I don’t feel comfortable interpreting somatic tumor testing results  (1)  
▢ I have not received training for interpreting somatic tumor testing results  (2)  
▢ The results wouldn’t contribute to my risk assessment  (3)  
▢ My institution doesn’t order somatic testing  (4)  
▢ We have other providers to do this  (5)  
▢ I don’t have time to review the results  (6)  
▢ My institution does not consider this part of the genetic counseling scope  (7)  
▢ Other  (8) ________________________________________________ 
 
Q33 Have you experienced or perceive any barriers to ordering somatic MMR testing? 
o Yes  (1)  
o No  (2)  
 
Q34 What are the barriers you have experienced or perceive? Select all that apply 
▢ Cost  (1)  
▢ Coordinating tissue samples  (2)  
▢ Lack of institution support  (3)  
▢ Unsure how to interpret the results  (4)  
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▢ Lack of time  (5)  
▢ Not available in-house  (6)  
▢ Not offered by preferred genetic testing lab(s)  (7)  
▢ Other  (8) ________________________________________________ 
 
Q35 Do/would you feel comfortable interpreting colon and/or uterine MMR somatic tumor testing 
results and including them in your risk assessment? 
o Extremely comfortable  (1)  
o Somewhat comfortable  (2)  
o Neither comfortable nor uncomfortable  (3)  
o Somewhat uncomfortable  (4)  
o Extremely uncomfortable  (5)  
 
Start of Block: Scenario 1 
Q36 The following questions refer to the scenario below:   
Mr. Smith is a 67-year old male recently diagnosed with colorectal cancer. Tumor testing revealed loss 
of staining in MLH1 and PMS2. MLH1 promoter methylation and BRAF mutation analysis were both 
negative. The patient's family history is below: 
 
Q38 What would you perceive this patient’s chance of having Lynch syndrome to be? 
o This patient absolutely has Lynch syndrome  (1)  
o It’s highly likely this patient has Lynch syndrome  (2)  
o It’s unlikely this patient has Lynch syndrome  (3)  
o This patient definitely does not have Lynch syndrome  (4)  
 
Q39 What would be your next step in evaluating this patient for Lynch syndrome? 
o Germline testing to include MMR genes  (1)  
o Germline testing to include MMR genes with reflex to somatic MMR testing if negative  (2)  
o Concurrent germline testing to include MMR genes plus somatic MMR testing  (3)  
o No further evaluation  (4)  
o Other  (5) ________________________________________________ 
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Q40 Somatic MMR testing reveals biallelic somatic mutations in MLH1. Germline testing for MMR 
genes was negative. Given this additional information, what do you perceive this patient’s chance of 
having Lynch syndrome to be? 
o This patient absolutely has Lynch syndrome  (1)  
o It’s highly likely this patient has Lynch syndrome  (2)  
o It’s unlikely this patient has Lynch syndrome  (3)  
o This patient definitely does not have Lynch syndrome  (4)  
 
Q41 What screening recommendations would you give this patient? 
o Population-level screening  (1)  
o Lynch syndrome screening  (2)  
o Other  (3) ________________________________________________ 
 
Q42 What screening recommendations would you give this patient’s first-degree relatives? 
o Population-level screening  (1)  
o Earlier colonoscopy based on family history  (2)  
o Lynch syndrome screening  (3)  
o Other  (4) ________________________________________________ 
 
Start of Block: Scenario 2 
Q43 The following questions refer to the scenario below:   
Ms. Jones is a 23-year old female recently diagnosed with colorectal cancer. Tumor testing revealed loss 
of staining in MSH2 and MSH6. The patient’s family history is below: 
 
 
Q44 What would you perceive this patient’s chance of having Lynch syndrome to be? 
o This patient absolutely has Lynch syndrome  (1)  
o It’s highly likely this patient has Lynch syndrome  (2)  
o It’s unlikely this patient has Lynch syndrome  (3)  
o This patient definitely does not have Lynch syndrome  (4)  
 
Q45 What would be your next step in evaluating this patient for Lynch syndrome? 
o Germline testing to include MMR genes  (1)  
o Germline testing to include MMR genes with reflex to somatic MMR testing if negative  (2)  
o Concurrent germline testing to include MMR genes plus somatic MMR testing  (3)  
o No further evaluation  (4)  
o Other  (5) ________________________________________________ 
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Q46 Somatic MMR testing reveals biallelic somatic mutations in MSH2. Germline testing for MMR 
genes was negative. Given this additional information, what do you perceive this patient’s chance of 
having Lynch syndrome to be? 
o This patient absolutely has Lynch syndrome  (1)  
o It’s highly likely this patient has Lynch syndrome  (2)  
o It’s unlikely this patient has Lynch syndrome  (3)  
o This patient definitely does not have Lynch syndrome  (4)  
 
Q47 What screening recommendations would you give this patient? 
o Population-level screening  (1)  
o Lynch syndrome screening  (2)  
o Other  (3) ________________________________________________ 
 
Q48 What screening recommendations would you give this patient’s first-degree relatives? 
o Population-level screening  (1)  
o Earlier colonoscopy based on family history  (2)  
o Lynch syndrome screening  (3)  
o Other  (4) ________________________________________________ 
 
Start of Block: Scenario 3 
Q49 The following questions refer to the scenario below:   
Ms. Davis is a 46-year old female recently diagnosed with uterine cancer. Tumor testing revealed loss of 
staining in MSH2 and MSH6. The patient’s family history is below: 
 
 
Q50 What would you perceive this patient’s chance of having Lynch syndrome to be? 
o This patient absolutely has Lynch syndrome  (1)  
o It’s highly likely this patient has Lynch syndrome  (2)  
o It’s unlikely this patient has Lynch syndrome  (3)  
o This patient definitely does not have Lynch syndrome  (4)  
 
Q51 What would be your next step in evaluating this patient for Lynch syndrome? 
o Germline testing to include MMR genes  (1)  
o Germline testing to include MMR genes with reflex to somatic MMR testing if negative  (2)  
o Concurrent germline testing to include MMR genes plus somatic MMR testing  (3)  
o No further evaluation  (4)  
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o Other  (5) ________________________________________________ 
 
Q52 Somatic MMR testing reveals a monoallelic somatic mutation in MSH2. Germline testing for MMR 
genes was negative. Given this additional information, what do you perceive this patient’s chance of 
having Lynch syndrome to be? 
o This patient absolutely has Lynch syndrome  (1)  
o It’s highly likely this patient has Lynch syndrome  (2)  
o It’s unlikely this patient has Lynch syndrome  (3)  
o This patient definitely does not have Lynch syndrome  (4)  
 
Q53 What screening recommendations would you give this patient? 
o Population-level screening  (1)  
o Lynch syndrome screening  (2)  
o Other  (3) ________________________________________________ 
 
Q54 What screening recommendations would you give this patient’s first-degree relatives? 
o Population-level screening  (1)  
o Earlier colonoscopy based on family history  (2)  
o Lynch syndrome screening  (3)  
o Other  (4) ________________________________________________ 
 
Start of Block: Scenario 4 
Q55 The following questions refer to the scenario below:   
Mr. Roberts is a 62-year old male recently diagnosed with colorectal cancer. Tumor testing revealed a 
loss of staining in MLH1 and PMS2. MLH1 promoter methylation and BRAF mutation analysis were 
both negative. The patient’s family history is below: 
 
Q56 What would you perceive this patient’s chance of having Lynch syndrome to be? 
o This patient absolutely has Lynch syndrome  (1)  
o It’s highly likely this patient has Lynch syndrome  (2)  
o It’s unlikely this patient has Lynch syndrome  (3)  
o This patient definitely does not have Lynch syndrome  (4)  
 
Q57 What would be your next step in evaluating this patient for Lynch syndrome? 
o Germline testing to include MMR genes  (1)  
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o Germline testing to include MMR genes with reflex to somatic MMR testing if negative  (2)  
o Concurrent germline testing to include MMR genes plus somatic MMR testing  (3)  
o No further evaluation  (4)  
o Other  (5) ________________________________________________ 
 
Q58 Somatic MMR testing and germline testing for MMR genes were both negative. Given this 
additional information, what do you perceive this patient’s chance of having Lynch syndrome to be? 
o This patient absolutely has Lynch syndrome  (1)  
o It’s highly likely this patient has Lynch syndrome  (2)  
o It’s unlikely this patient has Lynch syndrome  (3)  
o This patient definitely does not have Lynch syndrome  (4)  
 
Q59 What screening recommendations would you give this patient? 
o Population-level screening  (1)  
o Lynch syndrome screening  (2)  
o Other  (3) ________________________________________________ 
 
Q60 What screening recommendations would you give this patient’s first-degree relatives? 
o Population-level screening  (1)  
o Earlier colonoscopy based on family history  (2)  
o Lynch syndrome screening  (3)  
o Other  (4) ________________________________________________ 
Start of Block: Conclusion 
Q60 Would additional, more specific, national guidelines for ordering and/or the interpretation of MMR 
somatic tumor testing be beneficial to you? 
o Yes  (1)  
o Maybe  (2)  
o No  (3)  
o Unsure  (4)  
 
Q61 Do you have any additional comments that were not addressed by this survey? 
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